The use of the CAR T-cell therapy Kymriah (tisagenlecleucel) was effective with manageable side effects in patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of whether patients were children or young adults, according to registry data.
Findings from this registry were presented at the 2021 ASH Annual Meeting & Exposition.
In particular, Kymriah is an autologous T-cell product directed against CD-19, Dr. Samuel John, division chief of hematology/oncology and Distinguished Chair in Pediatric Oncology Research at UT Southwestern Medical Center in Dallas, Texas, said during the presentation. The T cells identify and kill the patient's leukemia cells.
In this study, researchers analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry of 561 patients up to age 25 years with relapsed/refractory B-cell acute lymphoblastic leukemia.
Acute lymphoblastic leukemia is the most common form of childhood cancer, John said during the presentation. This specific subtype, (B-cell acute lymphoblastic leukemia), accounts for greater than 80% of cases. Although the majority of pediatric patients with (B-cell acute lymphoblastic leukemia) have excellent outcomes, approximately 15% to 20% of patients will relapse. Outcomes for these patients are poor, with (a) five-year survival estimate of approximately 50%. Treatment options in the relapsed setting include intensified chemotherapy regimens, stem cell transplant and use of novel immunotherapy including chimeric antigen receptor T cells.
All patients in this registry were treated with Kymriah after August 30, 2017 either in the United States or Canada. Data were compared with the ELIANA trial, which was conducted before the treatment was approved for this indication.
(Kymriah) was approved in 2017 for the treatment of pediatric and young adult patients up to the age of 25 with relapsed refractory (B-cell acute lymphoblastic leukemia), John explained in the presentation. The CIBMTR collects data on these patients who received commercial (Kymriah). Early real-world data for (Kymriah) from the CIBMTR registry reported similar efficacy to that in the ELIANA clinical trial with no new safety signals.
Researchers performed age-specific analyses in patients younger than (389 patients) and older than 18 years (172 patients) at the time Kymriah was administered. Efficacy was evaluated in patients with at least 12 months of follow-up and included duration of response (the time a tumor responds to treatment without spreading or growing), overall response (patients with a partial or complete response to treatment), relapse-free survival (the time after treatment that a patient survives without signs or symptoms of cancer), event-free survival (the time after treatment that a patient is free from complications that the treatment was meant to delay or prevent) and overall survival (the time a patient with cancer is still alive). Patients who completed the first assessment at 100 days were part of the safety evaluation in this study.
Although most patient characteristics were comparable at the start of the study, there were some factors that differed by age group. Patients aged 18 years and older had greater disease burden than those younger than 18. In addition, older patients were more likely to be heavily pretreated before infusion versus the younger patients.
Efficacy in this study was assessed in 410 patients for a median of 25.9 months. Overall response rates in this registry were 86.8% compared with the 82.3% found in the ELIANA trial. Minimal residual disease status information was available for 195 patients, of whom 97.9% were considered minimal residual disease negative.
Event-free survival at 12 months in patients with available efficacy information was 52.6% compared with 57.2% from the ELIANA trial. In addition, the duration of response at 12 months was comparable in both studies (61.4% vs. 67.4%, respectively).
At 12 months, relapse-free survival was 62.5% compared with 66% from the ELIANA trial. Both age groups had similar rates of relapse-free survival and overall survival.
Researchers assessed safety in 493 patients for a median of 23.9 months. Most side effects were observed within the first 100 days of infusion. Safety outcomes in patients from the CIBMTR registry were more favorable than those from the ELIANA trial.
This may be related to a lower disease burden prior to T-cell infusion for patients treated with commercial (Kymriah), John said during the presentation.
From the registry, 22.9% of patients had prolonged neutropenia (low levels of a type of white blood cell called neutrophils) and 21.9% had prolonged thrombocytopenia (low levels of platelets that can lead to easy bruising and excessive bleeding). Safety data were mostly similar across age groups, although more patients aged 18 years and older had any-grade cytokine release syndrome (condition that may occur after certain types of immunotherapy that may result in fever, headache, nausea, low blood pressure, rapid heartbeat and trouble breathing) or neurotoxicity (nervous system damage). These side effects were subsequently treated.
Ongoing accrual of patient data into the CIBMTR registry will provide further insights into the use of (Kymriah) in the real-world setting, John concluded.
A version of this article originally appeared on OncLive as "Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes."
For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.
Here is the original post:
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments